Q-omics provides the consensus-scored PCA3 profile across patient tissues and cancer cell-line models. PCA3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, PCA3 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, PCA3 RNA expression shows 10,733 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CHOL, LIHC, and THYM as cancer lineages where PCA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCA3 survival associations across molecular data types. PCA3 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCA3 RNA expression–survival associations across cancer types. High PCA3 expression shows unfavorable associations in CHOL and BRCA, but favorable associations in KIRP, CESC, ESCA and KIRC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify CHOL as the clearest survival context for PCA3 RNA expression.
This table summarizes PCA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PCA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCA3 shows lower tumor expression in LIHC, KICH, KIRP, STAD and UCEC and higher tumor expression in PRAD. The LIHC box plot shows higher PCA3 RNA expression in normal versus tumor tissue (log2 FC = −0.060, t-test p < 0.001).
This table shows molecular features associated with PCA3 in patient tissues and cancer cell lines. In patient samples, PCA3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
